- Home
- EXK vs VRDN Comparison
EXK vs VRDN Comparison
Compare EXK & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EXK
- VRDN
- Stock Information
- Founded
- EXK 1981
- VRDN 2006
- Country
- EXK Canada
- VRDN United States
- Employees
- EXK N/A
- VRDN N/A
- Industry
- EXK Precious Metals
- VRDN Medical Specialities
- Sector
- EXK Basic Materials
- VRDN Health Care
- Exchange
- EXK Nasdaq
- VRDN Nasdaq
- Market Cap
- EXK 949.5M
- VRDN 1.0B
- IPO Year
- EXK N/A
- VRDN N/A
- Fundamental
- Price
- EXK $4.00
- VRDN $13.87
- Analyst Decision
- EXK Strong Buy
- VRDN Strong Buy
- Analyst Count
- EXK 3
- VRDN 12
- Target Price
- EXK $6.83
- VRDN $38.50
- AVG Volume (30 Days)
- EXK 13.5M
- VRDN 838.2K
- Earning Date
- EXK 05-13-2025
- VRDN 05-06-2025
- Dividend Yield
- EXK N/A
- VRDN N/A
- EPS Growth
- EXK N/A
- VRDN N/A
- EPS
- EXK N/A
- VRDN N/A
- Revenue
- EXK $217,412,000.00
- VRDN $302,000.00
- Revenue This Year
- EXK $99.18
- VRDN N/A
- Revenue Next Year
- EXK $49.21
- VRDN $21,976.14
- P/E Ratio
- EXK N/A
- VRDN N/A
- Revenue Growth
- EXK 1.72
- VRDN 4.86
- 52 Week Low
- EXK $2.46
- VRDN $9.90
- 52 Week High
- EXK $5.67
- VRDN $27.20
- Technical
- Relative Strength Index (RSI)
- EXK 63.02
- VRDN 55.33
- Support Level
- EXK $3.50
- VRDN $13.37
- Resistance Level
- EXK $3.72
- VRDN $14.18
- Average True Range (ATR)
- EXK 0.18
- VRDN 0.67
- MACD
- EXK 0.06
- VRDN 0.12
- Stochastic Oscillator
- EXK 89.58
- VRDN 71.43
About EXK Endeavour Silver Corporation (Canada)
Endeavour Silver Corp is a Canadian mineral company engaged in the evaluation, acquisition, exploration, development, and exploitation of precious metal properties in Mexico and Chile. The Company has two operating mining segments which are located in Mexico, Guanacevi and Bolanitos. The company has one development project in Mexico, Terronera, as well as Exploration and Corporate segments. The Exploration segment consists of projects in the exploration and evaluation phases in Mexico, Chile, and the USA.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).